Myocardial Infarction Triage and Intervention Project (MITI)
NCT ID: NCT00000468
Last Updated: 2016-02-09
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE3
Study Classification
INTERVENTIONAL
Study Start Date
1988-04-30
Study Completion Date
1992-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To determine the practicality, benefit, and safety of paramedic administration of thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly identifying candidates for thrombolytic therapy following myocardial infarction was assessed in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital thrombolytic therapy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Thrombolysis in Myocardial Infarction (TIMI)
NCT00000505
Cardiovascular Diseases
Coronary Disease
Heart Diseases
+2 more
COMPLETED
PHASE3
Safety and Effectiveness of Intra-coronary Nitrite in Acute Myocardial Infarction
NCT01584453
Myocardial Infarction
Reperfusion Injury
Myocardial Ischemia
+1 more
COMPLETED
PHASE2
Surveillance of Patients With Suspected Acute Myocardial Infarction That Receive Early Inhospital Thrombolysis With Metalyse
NCT02194153
Myocardial Infarction
COMPLETED
Intracoronary Cocktail Injection Combined With Thrombus Aspiration in STEMI Patients Treated With Primary Angioplasty
NCT02592694
ST-elevation Myocardial Infarction
UNKNOWN
PHASE4
Rheolytic Thrombectomy in Patients With Acute STEMI and Large Thrombus Burden
NCT02604394
ST Elevation Myocardial Infarction
STEMI
UNKNOWN
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
BACKGROUND:
In the past, patients with acute myocardial infarction were treated by putting them to bed. It was felt that once the symptoms and electrocardiographic signs of acute myocardial infarction had occurred, the process was complete and that the heart and patient at rest would allow the illness to run its course and the heart to heal. The focus of treatment in the Coronary Intensive Care Unit was to prevent complications of acute myocardial infarction, primarily arrhythmias leading to cardiac arrest and the treatment of cardiac arrest itself. Acute phase morbidity and mortality related to loss of myocardium through infarction has not changed. Post-discharge mortality and morbidity is, in large part, related to the occurrence of congestive heart failure, secondary to loss of myocardium to infarction. Efforts to preserve myocardium through pharmacologic intervention to limit demand, have not resulted in significant benefit. It is now recognized that the infarction is not complete on presentation, that it occurs as a wavefront over a period of four to six hours, and that in 80 to 90 percent of patients, infarction is due to thrombus in the infarct-related artery. Therefore, reperfusion of the jeopardized myocardium during this window of four to six hours could result in salvage of myocardium with resultant decrease in acute mortality as well as acute and chronic morbidity and mortality from myocardial failure.
The international streptokinase trials have established the feasibility of intravenous coronary thrombolysis with streptokinase and demonstrated a decrease in acute morality ranging from 18 percent to 50 percent, depending upon the interval between the onset of chest pain and the initiation of thrombolytic therapy. Furthermore, preservation of ventricular function, as reflected in ejection fraction, is greater with early administration.
The TIMI trial of tissue plasminogen activator (TPA), which is more clot-specific than streptokinase, has substantiated the effectiveness. The initiation of thrombolytic therapy with TPA as early as possible after the onset of symptoms offers an advantage, therefore, in terms of both a reduction in acute mortality and salvage of ischemic myocardium.
Although thrombolysis is being performed at community hospitals or enroute to hospitals by specially trained teams using helicopter transport, only one major study has been reported which has systematically evaluated the benefit of early on-the-scene thrombolysis. This study documented significant benefit in terms of salvage of myocardium over those patients in whom thrombolytic therapy was initiated after arrival in the hospital, as a direct function of time. This program used physicians in the ambulance to evaluate indications for and contraindications to thrombolytic therapy in the field. The proposed study would evaluate the ability of paramedics, under physician remote control, to accurately evaluate patients in the field in terms of indications and contra-indications to thrombolytic therapy, and to assess the possible benefit in terms of salvage of myocardium in those patients being transported to the hospital by paramedic squads as opposed to those arriving by ordinary means.
DESIGN NARRATIVE:
In Phase I, the paramedics took electrocardiograms of patients who met the definition of cases and administered an abbreviated questionnaire. This phase tested the feasibility of paramedics making a diagnosis of acute myocardial infarction on the basis of clinical history and with the support of computerized electrocardiogram, coming to an appropriate decision to initiate thrombolytic therapy on the basis of the field database, and recognizing appropriate contraindications to thrombolytic therapy with and without remote physician supervision. An analysis was conducted of the pre-hospital selection of patients for thrombolytic therapy.
Criteria for approval to move to Phase II included correct identification of appropriate cases for treatment 75 percent of the time, less than five percent inappropriate cases or with contraindications for thrombolytic therapy, and no more than one percent of the selected cases found to have initial life-threatening hemorrhagic conditions.
Beginning in November 1988, Phase II compared initiation of thrombolysis with tissue plasminogen activator (TPA) in the field to initiation in the hospital. During Phase II, which lasted for 24 months, one half of the patients meeting the case definition received paramedic administration of intravenous thrombolytic therapy and one half received the same pre-hospital diagnostic steps but treatment administered after transport to the hospital. The 360 patients with symptoms for six hours or less, no risk factors for serious bleeding, and ST-segment elevation, were selected by paramedics and a remote physician for inclusion in the trial. They were allocated to aspirin and alteplase treatment initiated before or after hospital arrival. Intravenous sodium heparin was administered to both groups in the hospital. Nineteen hospitals in the Seattle and King County areas participated. The primary endpoint was a ranked composite score (combining death, stroke, serious bleeding, and infarct size). The relation between time to treatment and outcome (composite score, infarct size, ejection fraction, and mortality) was also assessed.
In Phase II, a myocardial infarction registry was established to include all patients hospitalized in the area with a discharge diagnosis of acute myocardial infarction. The registry placed the trial findings in a community-based perspective and aided in the interpretation of trial findings by assessing the proportion of cases seeking paramedic care and determining the characteristics of these patients in contrast to those arriving at the hospital by other means. The records of all patients admitted directly to coronary care units in Seattle and King County were surveyed. Study personnel examined differences, if any, between paramedic and other transport groups regarding clinical history, treatment, complications, and hospital discharge rates. Of the cases in the registry, 300 who arrived at the hospital by means other than paramedic transport were compared to the paramedic-transported cases with respect to the incidence of new Q-wave infarction on the first and last electrocardiogram, an interview to determine onset, severity, and duration of symptoms, and reasons for choosing one type of care over the other during the emergency situation.
In the past, patients with acute myocardial infarction were treated by putting them to bed. It was felt that once the symptoms and electrocardiographic signs of acute myocardial infarction had occurred, the process was complete and that the heart and patient at rest would allow the illness to run its course and the heart to heal. The focus of treatment in the Coronary Intensive Care Unit was to prevent complications of acute myocardial infarction, primarily arrhythmias leading to cardiac arrest and the treatment of cardiac arrest itself. Acute phase morbidity and mortality related to loss of myocardium through infarction has not changed. Post-discharge mortality and morbidity is, in large part, related to the occurrence of congestive heart failure, secondary to loss of myocardium to infarction. Efforts to preserve myocardium through pharmacologic intervention to limit demand, have not resulted in significant benefit. It is now recognized that the infarction is not complete on presentation, that it occurs as a wavefront over a period of four to six hours, and that in 80 to 90 percent of patients, infarction is due to thrombus in the infarct-related artery. Therefore, reperfusion of the jeopardized myocardium during this window of four to six hours could result in salvage of myocardium with resultant decrease in acute mortality as well as acute and chronic morbidity and mortality from myocardial failure.
The international streptokinase trials have established the feasibility of intravenous coronary thrombolysis with streptokinase and demonstrated a decrease in acute morality ranging from 18 percent to 50 percent, depending upon the interval between the onset of chest pain and the initiation of thrombolytic therapy. Furthermore, preservation of ventricular function, as reflected in ejection fraction, is greater with early administration.
The TIMI trial of tissue plasminogen activator (TPA), which is more clot-specific than streptokinase, has substantiated the effectiveness. The initiation of thrombolytic therapy with TPA as early as possible after the onset of symptoms offers an advantage, therefore, in terms of both a reduction in acute mortality and salvage of ischemic myocardium.
Although thrombolysis is being performed at community hospitals or enroute to hospitals by specially trained teams using helicopter transport, only one major study has been reported which has systematically evaluated the benefit of early on-the-scene thrombolysis. This study documented significant benefit in terms of salvage of myocardium over those patients in whom thrombolytic therapy was initiated after arrival in the hospital, as a direct function of time. This program used physicians in the ambulance to evaluate indications for and contraindications to thrombolytic therapy in the field. The proposed study would evaluate the ability of paramedics, under physician remote control, to accurately evaluate patients in the field in terms of indications and contra-indications to thrombolytic therapy, and to assess the possible benefit in terms of salvage of myocardium in those patients being transported to the hospital by paramedic squads as opposed to those arriving by ordinary means.
DESIGN NARRATIVE:
In Phase I, the paramedics took electrocardiograms of patients who met the definition of cases and administered an abbreviated questionnaire. This phase tested the feasibility of paramedics making a diagnosis of acute myocardial infarction on the basis of clinical history and with the support of computerized electrocardiogram, coming to an appropriate decision to initiate thrombolytic therapy on the basis of the field database, and recognizing appropriate contraindications to thrombolytic therapy with and without remote physician supervision. An analysis was conducted of the pre-hospital selection of patients for thrombolytic therapy.
Criteria for approval to move to Phase II included correct identification of appropriate cases for treatment 75 percent of the time, less than five percent inappropriate cases or with contraindications for thrombolytic therapy, and no more than one percent of the selected cases found to have initial life-threatening hemorrhagic conditions.
Beginning in November 1988, Phase II compared initiation of thrombolysis with tissue plasminogen activator (TPA) in the field to initiation in the hospital. During Phase II, which lasted for 24 months, one half of the patients meeting the case definition received paramedic administration of intravenous thrombolytic therapy and one half received the same pre-hospital diagnostic steps but treatment administered after transport to the hospital. The 360 patients with symptoms for six hours or less, no risk factors for serious bleeding, and ST-segment elevation, were selected by paramedics and a remote physician for inclusion in the trial. They were allocated to aspirin and alteplase treatment initiated before or after hospital arrival. Intravenous sodium heparin was administered to both groups in the hospital. Nineteen hospitals in the Seattle and King County areas participated. The primary endpoint was a ranked composite score (combining death, stroke, serious bleeding, and infarct size). The relation between time to treatment and outcome (composite score, infarct size, ejection fraction, and mortality) was also assessed.
In Phase II, a myocardial infarction registry was established to include all patients hospitalized in the area with a discharge diagnosis of acute myocardial infarction. The registry placed the trial findings in a community-based perspective and aided in the interpretation of trial findings by assessing the proportion of cases seeking paramedic care and determining the characteristics of these patients in contrast to those arriving at the hospital by other means. The records of all patients admitted directly to coronary care units in Seattle and King County were surveyed. Study personnel examined differences, if any, between paramedic and other transport groups regarding clinical history, treatment, complications, and hospital discharge rates. Of the cases in the registry, 300 who arrived at the hospital by means other than paramedic transport were compared to the paramedic-transported cases with respect to the incidence of new Q-wave infarction on the first and last electrocardiogram, an interview to determine onset, severity, and duration of symptoms, and reasons for choosing one type of care over the other during the emergency situation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Cardiovascular Diseases
Coronary Disease
Heart Diseases
Myocardial Infarction
Myocardial Ischemia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Primary Study Purpose
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tissue plasminogen activator
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Men and women, ages 35 to 71, with chest pain of between 15 minutes and 6 hours duration, systolic blood pressure of more than 80 mm Hg and less than 200 mm Hg, and a diastolic blood pressure of less than 120 mm Hg. (Phase I).
Men and women with m
Men and women with m
Minimum Eligible Age
35 Years
Maximum Eligible Age
71 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Sponsor Role
collaborator
University of Washington
OTHER
Sponsor Role
lead
References
Explore related publications, articles, or registry entries linked to this study.
Every NR, Parsons LS, Hlatky M, Martin JS, Weaver WD. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. Myocardial Infarction Triage and Intervention Investigators. N Engl J Med. 1996 Oct 24;335(17):1253-60. doi: 10.1056/NEJM199610243351701.
Reference Type
BACKGROUND
Every NR, Maynard C, Cochran RP, Martin J, Weaver WD. Characteristics, management, and outcome of patients with acute myocardial infarction treated with bypass surgery. Myocardial Infarction Triage and Intervention Investigators. Circulation. 1996 Nov 1;94(9 Suppl):II81-6.
Reference Type
BACKGROUND
Weaver WD, Eisenberg MS, Martin JS, Litwin PE, Shaeffer SM, Ho MT, Kudenchuk P, Hallstrom AP, Cerqueira MD, Copass MK, et al. Myocardial Infarction Triage and Intervention Project--phase I: patient characteristics and feasibility of prehospital initiation of thrombolytic therapy. J Am Coll Cardiol. 1990 Apr;15(5):925-31. doi: 10.1016/0735-1097(90)90218-e.
Reference Type
BACKGROUND
Martin JS, Litwin PE, Weaver WD. Early recognition and treatment of the patient suffering from acute myocardial infarction. A description of the Myocardial Infarction Triage and Intervention Project. Crit Care Nurs Clin North Am. 1990 Dec;2(4):681-8.
Reference Type
BACKGROUND
Kennedy JW, Weaver WD. The potential for prehospital thrombolytic therapy. Clin Cardiol. 1990 Aug;13(8 Suppl 8):VIII23-6.
Reference Type
BACKGROUND
Kudenchuk PJ, Ho MT, Weaver WD, Litwin PE, Martin JS, Eisenberg MS, Hallstrom AP, Cobb LA, Kennedy JW. Accuracy of computer-interpreted electrocardiography in selecting patients for thrombolytic therapy. MITI Project Investigators. J Am Coll Cardiol. 1991 Jun;17(7):1486-91. doi: 10.1016/0735-1097(91)90636-n.
Reference Type
BACKGROUND
Weaver WD, Litwin PE, Martin JS, Kudenchuk PJ, Maynard C, Eisenberg MS, Ho MT, Cobb LA, Kennedy JW, Wirkus MS. Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction. The MITI Project Group. J Am Coll Cardiol. 1991 Sep;18(3):657-62. doi: 10.1016/0735-1097(91)90784-7.
Reference Type
BACKGROUND
Maynard C, Litwin PE, Martin JS, Cerqueira M, Kudenchuk PJ, Ho MT, Kennedy JW, Cobb LA, Schaeffer SM, Hallstrom AP, et al. Characteristics of black patients admitted to coronary care units in metropolitan Seattle: results from the Myocardial Infarction Triage and Intervention Registry (MITI). Am J Cardiol. 1991 Jan 1;67(1):18-23. doi: 10.1016/0002-9149(91)90092-y.
Reference Type
BACKGROUND
Hallstrom AP, Litwin PE, Weaver WD. A method of assigning scores to the components of a composite outcome: an example from the MITI trial. Control Clin Trials. 1992 Apr;13(2):148-55. doi: 10.1016/0197-2456(92)90020-z.
Reference Type
BACKGROUND
Maynard C, Litwin PE, Martin JS, Weaver WD. Gender differences in the treatment and outcome of acute myocardial infarction. Results from the Myocardial Infarction Triage and Intervention Registry. Arch Intern Med. 1992 May;152(5):972-6.
Reference Type
BACKGROUND
Every NR, Larson EB, Litwin PE, Maynard C, Fihn SD, Eisenberg MS, Hallstrom AP, Martin JS, Weaver WD. The association between on-site cardiac catheterization facilities and the use of coronary angiography after acute myocardial infarction. Myocardial Infarction Triage and Intervention Project Investigators. N Engl J Med. 1993 Aug 19;329(8):546-51. doi: 10.1056/NEJM199308193290807.
Reference Type
BACKGROUND
Weaver WD, Cerqueira M, Hallstrom AP, Litwin PE, Martin JS, Kudenchuk PJ, Eisenberg M. Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA. 1993 Sep 8;270(10):1211-6.
Reference Type
BACKGROUND
Longstreth WT Jr, Litwin PE, Weaver WD. Myocardial infarction, thrombolytic therapy, and stroke. A community-based study. The MITI Project Group. Stroke. 1993 Apr;24(4):587-90. doi: 10.1161/01.str.24.4.587.
Reference Type
BACKGROUND
Maynard C, Weaver WD, Litwin PE, Martin JS, Kudenchuk PJ, Dewhurst TA, Eisenberg MS, Hallstrom AP, Chambers J. Hospital mortality in acute myocardial infarction in the era of reperfusion therapy (the Myocardial Infarction Triage and Intervention Project). Am J Cardiol. 1993 Oct 15;72(12):877-82. doi: 10.1016/0002-9149(93)91099-4.
Reference Type
BACKGROUND
Weaver WD, Litwin PE, Martin JS. Use of direct angioplasty for treatment of patients with acute myocardial infarction in hospitals with and without on-site cardiac surgery. The Myocardial Infarction, Triage, and Intervention Project Investigators. Circulation. 1993 Nov;88(5 Pt 1):2067-75. doi: 10.1161/01.cir.88.5.2067.
Reference Type
BACKGROUND
Every NR, Fihn SD, Maynard C, Martin JS, Weaver WD. Resource utilization in treatment of acute myocardial infarction: staff-model health maintenance organization versus fee-for-service hospitals. The MITI Investigators. Myocardial Infarction Triage and Intervention. J Am Coll Cardiol. 1995 Aug;26(2):401-6. doi: 10.1016/0735-1097(95)80013-7.
Reference Type
BACKGROUND
Kudenchuk PJ, Maynard C, Martin JS, Wirkus M, Weaver WD. Comparison of presentation, treatment, and outcome of acute myocardial infarction in men versus women (the Myocardial Infarction Triage and Intervention Registry). Am J Cardiol. 1996 Jul 1;78(1):9-14. doi: 10.1016/s0002-9149(96)00218-4.
Reference Type
BACKGROUND
Every NR, Spertus J, Fihn SD, Hlatky M, Martin JS, Weaver WD. Length of hospital stay after acute myocardial infarction in the Myocardial Infarction Triage and Intervention (MITI) Project registry. J Am Coll Cardiol. 1996 Aug;28(2):287-93. doi: 10.1016/0735-1097(96)00168-4.
Reference Type
BACKGROUND
Brouwer MA, Martin JS, Maynard C, Wirkus M, Litwin PE, Verheugt FW, Weaver WD. Influence of early prehospital thrombolysis on mortality and event-free survival (the Myocardial Infarction Triage and Intervention [MITI] Randomized Trial). MITI Project Investigators. Am J Cardiol. 1996 Sep 1;78(5):497-502. doi: 10.1016/s0002-9149(96)00352-9.
Reference Type
BACKGROUND
Spertus JA, Weiss NS, Every NR, Weaver WD. The influence of clinical risk factors on the use of angiography and revascularization after acute myocardial infarction. Myocardial Infarction Triage and Intervention Project Investigators. Arch Intern Med. 1995 Nov 27;155(21):2309-16.
Reference Type
BACKGROUND
Maynard C, Every NR, Litwin PE, Martin JS, Weaver WD. Outcomes in African-American women with suspected acute myocardial infarction: the Myocardial Infarction Triage and Intervention Project. J Natl Med Assoc. 1995 May;87(5):339-44.
Reference Type
BACKGROUND
Every NR, Parsons LS, Fihn SD, Larson EB, Maynard C, Hallstrom AP, Martin JS, Weaver WD. Long-term outcome in acute myocardial infarction patients admitted to hospitals with and without on-site cardiac catheterization facilities. MITI Investigators. Myocardial Infarction Triage and Intervention. Circulation. 1997 Sep 16;96(6):1770-5. doi: 10.1161/01.cir.96.6.1770.
Reference Type
BACKGROUND
Maynard C, Every NR, Martin JS, Weaver WD. Long-term implications of racial differences in the use of revascularization procedures (the Myocardial Infarction Triage and Intervention registry). Am Heart J. 1997 Jun;133(6):656-62. doi: 10.1016/s0002-8703(97)70167-4.
Reference Type
BACKGROUND
Kudenchuk PJ, Maynard C, Cobb LA, Wirkus M, Martin JS, Kennedy JW, Weaver WD. Utility of the prehospital electrocardiogram in diagnosing acute coronary syndromes: the Myocardial Infarction Triage and Intervention (MITI) Project. J Am Coll Cardiol. 1998 Jul;32(1):17-27. doi: 10.1016/s0735-1097(98)00175-2.
Reference Type
BACKGROUND
Scull GS, Martin JS, Weaver WD, Every NR. Early angiography versus conservative treatment in patients with non-ST elevation acute myocardial infarction: MITI Investigators. Myocardial Infarction Triage and Intervention. J Am Coll Cardiol. 2000 Mar 15;35(4):895-902. doi: 10.1016/s0735-1097(99)00643-9.
Reference Type
BACKGROUND
Maynard C, Martin JS, Hallstrom AP, Weaver WD. Changes in the Use of Thrombolytic Therapy in Seattle Area Hospitals from 1988 to 1992: Results from the Myocardial Infarction Triage and Intervention Registry. J Thromb Thrombolysis. 1995;1(2):195-199. doi: 10.1007/BF01062578.
Reference Type
BACKGROUND
Kim C, Schaaf CH, Maynard C, Every NR. Unstable angina in the myocardial infarction triage and intervention registry (MITI): short- and long-term outcomes in men and women. Am Heart J. 2001 Jan;141(1):73-7. doi: 10.1067/mhj.2001.111546.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
57
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Thrombectomy in Acute Myocardial Infarction
NCT00675480
COMPLETED
PHASE3
Thrombolysis in Myocardial Ischemia Trial (TIMI III)
NCT00000472
COMPLETED
PHASE3
Intravenous Streptokinase in Acute Myocardial Infarction
NCT00000507
COMPLETED
PHASE3
Concomitant Milrinone and Esmolol Treatment in Patients with Acute Myocardial Infarction
NCT02098629
COMPLETED
PHASE2
Nitrites in Acute Myocardial Infarction
NCT01388504
COMPLETED
PHASE2/PHASE3
Long-term Remote Ischemic Preconditioning Improve Long-term Prognosis of Acute Myocardial Infarction Patients Without Emergency Reperfusion Therapy
NCT02843464
UNKNOWN
NA
Low-Level Transcutaneous Vagus Stimulation in ST Segment Elevation Myocardial Infarction: TREAT MI Study
NCT03284281
WITHDRAWN
NA
Sodium Thiosulfate to Preserve Cardiac Function in STEMI
NCT02899364
UNKNOWN
PHASE2
Efficacy and Safety of Prehospital Administration of Bivalirudin in STEMI Patients
NCT00391326
COMPLETED
A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)
NCT00046228
COMPLETED
PHASE3
The Effect of Erythropoietin at the Time of Reperfusion in Acute Myocardial Infarction
NCT00882466
COMPLETED
PHASE4
Randomized Clinical Trial of Non-Surgical Reperfusion of the Coronary Arteries
NCT00000503
COMPLETED
PHASE3
Thrombus Aspiration in Patients With STEMI
NCT02606435
UNKNOWN
PHASE4
Morphine In Acute Myocardial Infarction
NCT01186445
COMPLETED
PHASE3
Comparison Between Thrombolysis and Primary Percutaneous Coronary Intervention (PCI) to Treat ST-Segment Elevation Myocardial Infarction
NCT00806403
COMPLETED
PHASE4
The Thrombus Aspiration During PCI After Thrombolysis in STEMI
NCT06654453
NOT_YET_RECRUITING
NA
Adjunctive, Low-dose tPA in Primary PCI for STEMI
NCT03335839
COMPLETED
PHASE3
Antiplatelets and Intramyocardial Hemorrhage in STEMI: Incidence and Outcomes
NCT06851325
COMPLETED
Drug Elution and Distal Protection During Percutaneous Coronary Intervention in ST Elevation Myocardial Infarction
NCT00192868
UNKNOWN
NA
Remote Ischemic Perconditioning in Patients With ST-segment Elevation Myocardial Infarction
NCT02164695
COMPLETED
NA
Nitric Oxide in Myocardial Infarction Size
NCT00568061
TERMINATED
PHASE2
Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden
NCT06769256
RECRUITING
PHASE4
A Study of Pre-hospital Treatment of Acute Myocardial Infarction Based on Diagnosis by Interpretation of Remotely Acquired ECG and Thrombolysis With Accelerated Alteplase ( Actilyse®)
NCT02235389
TERMINATED
Long-term Remote Ischemic Preconditioning Improve the Prognosis of Myocardial Infarction Patients With Emergency Reperfusion Therapy
NCT03018873
UNKNOWN
NA
Revascularization StrategIes for ST Elevation Myocardial Infarction Trial
NCT03263468
UNKNOWN
NA